The Misuse Question in Telehealth Ketamine
Ketamine is a Schedule III controlled substance with recognized therapeutic value and recognized potential for misuse. When a patient receives ketamine at home through a telehealth program — rather than under direct supervision in a clinic — the question of how misuse is prevented becomes critically important.
This is not a theoretical concern. The DEA, state medical boards, and the clinical community all recognize that at-home ketamine programs must implement specific safeguards to minimize the risk of diversion (medication reaching unintended recipients) and misuse (patients using the medication outside of prescribed protocols). Legitimate telehealth ketamine providers take this responsibility seriously and employ multiple overlapping strategies.
Understanding what safeguards telehealth ketamine programs use to prevent misuse helps patients evaluate providers and helps concerned family members, therapists, and primary care physicians understand the protective measures in place.
Pre-Enrollment Safeguards
Substance Use History Screening
The first line of defense against ketamine misuse begins before a single dose is prescribed. During the intake evaluation, responsible providers conduct a thorough substance use assessment that covers:
- Current substance use: Alcohol consumption, cannabis use, recreational drug use, and use of other controlled substances
- History of substance use disorders: Previous diagnoses of dependence or addiction involving any substance
- History of ketamine use: Prior recreational or therapeutic ketamine use and the patient's relationship with the substance
- Family history: Family history of substance use disorders, which affects individual risk
- Treatment for substance use: Previous or current involvement in substance use treatment programs
Patients with active substance use disorders — particularly involving dissociative drugs, opioids, or alcohol — may be excluded from at-home ketamine programs (see our patient selection criteria) or may be required to demonstrate a period of stability and engagement with addiction treatment before being considered.
This screening is imperfect. Patients can minimize or conceal their substance use history. But a thorough evaluation by a trained clinician significantly reduces the pool of high-risk individuals entering the program.
Psychological Risk Assessment
Beyond substance use specifically, responsible programs assess broader psychological risk factors for misuse:
- Motivation for treatment: Is the patient seeking symptom relief for a diagnosed condition, or are they primarily interested in the dissociative experience?
- Treatment expectations: Does the patient understand that ketamine is a medical treatment, not a recreational experience?
- Coping mechanisms: How does the patient typically cope with distress? Patients who rely heavily on substance use as a coping strategy may be at higher risk
- Support system: Does the patient have a stable living situation and supportive relationships?
These factors do not automatically disqualify patients, but they inform the level of monitoring and the appropriateness of at-home treatment versus in-clinic alternatives.
Prescription Drug Monitoring Program (PDMP) Checks
PDMPs are state-run electronic databases that track controlled substance prescriptions dispensed to individual patients. When a telehealth ketamine provider checks the PDMP, they can identify:
- Whether the patient is receiving ketamine prescriptions from other providers (potential "doctor shopping")
- Whether the patient is receiving other controlled substances that might indicate higher misuse risk or dangerous drug interactions
- Patterns of early refills or high-volume controlled substance use across multiple providers
PDMP checks are required by law in most states before prescribing controlled substances. Legitimate telehealth ketamine providers run these checks at intake and periodically throughout treatment. A provider that does not check the PDMP is failing a basic regulatory and clinical obligation. For more on regulatory requirements, see our DEA compliance guide.
Prescription-Level Safeguards
Limited Quantities
One of the most straightforward safeguards is limiting the quantity of ketamine dispensed at any one time. Rather than prescribing a large supply, responsible programs typically:
- Prescribe enough medication for a defined number of sessions (often 4-6 sessions per shipment)
- Require clinical check-ins before authorizing refills
- Ship medication in quantities that limit the potential for significant misuse or diversion
This approach means that even if a patient does misuse the medication, the amount available at any one time is limited. It also creates natural checkpoints where the clinical team can reassess.
Structured Dosing Protocols
Legitimate programs prescribe specific doses for specific session schedules. Patients receive instructions to take a defined dose at defined intervals — for example, one session per week using one troche per session. This structured protocol differs meaningfully from an open-ended prescription that could be used at the patient's discretion.
Structured dosing accomplishes several things:
- It establishes clear expectations about how much medication should be used and when
- It makes deviations detectable (running out early, requesting extra medication)
- It prevents dose escalation without clinical oversight
- It reinforces that ketamine is a structured medical treatment, not a self-directed experience
Dose Tracking and Accountability
Some telehealth providers implement dose tracking systems where patients log each session — when they took the medication, the dose, and their experience. Discrepancies between the amount prescribed and the amount used (based on session logs and refill timing) can indicate off-protocol use.
While this tracking relies partly on patient self-reporting, it creates a framework of accountability that discourages casual misuse. Patients who know their use is being tracked are less likely to deviate from the protocol.
During-Treatment Safeguards
Regular Clinical Check-Ins
Ongoing clinical contact is both a therapeutic tool and a misuse prevention strategy. During follow-up appointments, clinicians can:
- Assess the patient's response to treatment using standardized measures (PHQ-9, GAD-7, etc.)
- Ask about the treatment experience in ways that reveal whether the patient is using the medication as prescribed
- Screen for emerging patterns of misuse (dose escalation, using medication for recreational purposes, taking ketamine outside of scheduled sessions)
- Evaluate whether the patient's relationship with the medication is therapeutic or has shifted toward dependency
Clinicians trained in addiction medicine recognize behavioral markers of developing dependence — preoccupation with the medication, anxiety about running out, using the substance to manage acute emotional crises rather than following the prescribed protocol, and resistance to dose reduction or tapering.
Session Sitter Reports
Many telehealth ketamine programs require a sober adult present during sessions. The session sitter serves a dual safety function — both medical emergency response and behavioral observation. Some programs ask sitters to confirm that the session occurred as described by the patient.
A sitter who observes concerning behavior — such as the patient taking more medication than prescribed, using the medication at unscheduled times, or exhibiting signs of intoxication outside of session times — can alert the clinical team.
Behavioral Monitoring
Beyond clinical check-ins, some programs monitor behavioral signals that may indicate misuse:
- Refill patterns: Requesting refills earlier than expected
- Dose increase requests: Frequent requests for dose increases without clinical improvement
- Contact patterns: Calling or messaging with urgency about medication access
- Session compliance: Missing follow-up appointments while continuing to request medication
- Outcome stagnation: Continuing to request ketamine despite no improvement in measured symptoms
None of these signals alone confirms misuse, but patterns of multiple concerning behaviors trigger clinical review.
Pharmacy-Level Safeguards
Compounding Pharmacy Controls
The licensed compounding pharmacies that prepare and ship ketamine for telehealth programs maintain their own safeguards:
- Verification of prescriber DEA registration before dispensing
- PDMP reporting of every ketamine prescription dispensed
- Tracking of shipment delivery to confirm medication reaches the intended patient
- Requirements for signature upon delivery in some cases
- Internal review for unusual prescribing patterns from their provider partners
Packaging and Labeling
Medication is shipped in clearly labeled packaging that identifies the contents, the prescribed dose, the patient, and the prescribing provider. This packaging creates a chain of accountability from pharmacy to patient.
Some pharmacies use packaging that makes it evident if the medication has been tampered with or partially removed, adding another layer of accountability.
System-Level Safeguards
Treatment Agreements
Many programs require patients to sign treatment agreements (sometimes called "controlled substance agreements") that explicitly outline:
- The patient will use ketamine only as prescribed
- The patient will not share or sell the medication
- The patient will store the medication securely
- The patient will attend all required follow-up appointments
- The patient consents to PDMP checks
- Violations of the agreement may result in discharge from the program
While a treatment agreement does not physically prevent misuse, it establishes clear expectations and creates a documented basis for discontinuing treatment if misuse is identified.
Internal Clinical Review
Responsible programs conduct internal reviews of their patient populations, looking for patterns that might indicate systemic issues:
- Are certain prescribers approving significantly more patients than others?
- Are refill rates higher than expected across the patient population?
- Are adverse event reports increasing?
- Are patients dropping out of the monitoring components while continuing to receive medication?
These population-level reviews help programs identify weaknesses in their own safeguards and adjust accordingly.
Discharge Protocols for Misuse
Legitimate programs have clear protocols for what happens when misuse is identified:
- Clinical conversation with the patient about the concerning behavior
- Assessment of whether the behavior reflects misuse, confusion about the protocol, or another explanation
- Increased monitoring if the behavior is ambiguous
- Treatment modification (dose reduction, increased check-in frequency, requirement for in-person sitter)
- Discharge from the program if misuse is confirmed, with referral to substance use treatment resources
- PDMP notation and, if required, reporting to relevant authorities
Discharge for misuse should not be punitive — it should include referral to appropriate treatment. But programs have an ethical and legal obligation to stop prescribing a controlled substance to patients who are misusing it.
Limitations of Current Safeguards
No system of safeguards is perfect. It is important to acknowledge the limitations:
- Patient dishonesty: Patients who are determined to misuse ketamine can lie on screening questionnaires, underreport their use, and manipulate the system
- Measurement challenges: There is no reliable biomarker or test that distinguishes therapeutic use from misuse in real time
- Remote setting: At-home treatment inherently provides less oversight than in-clinic administration
- Commercial pressure: Providers that depend on patient enrollment for revenue may face implicit pressure to retain patients rather than discharge them for concerning behavior
These limitations do not make at-home ketamine programs irresponsible. They make robust, multi-layered safeguards essential. No single safeguard is sufficient, but the combination of screening, limited quantities, structured protocols, regular monitoring, PDMP checks, and discharge protocols creates a system where misuse is difficult to sustain undetected.
What Patients Can Do
Patients who want to use ketamine responsibly can support the safeguard system by:
- Being honest about substance use history during screening
- Following the prescribed protocol exactly
- Attending all follow-up appointments
- Reporting concerns about their own relationship with the medication
- Storing medication securely and away from others in the household
- Asking for help if they notice themselves wanting to use the medication outside of sessions
The most powerful safeguard is a genuine therapeutic relationship in which patients feel safe being honest about their experience — including any temptation to misuse. Programs that create an atmosphere of trust rather than surveillance tend to identify problems earlier because patients are willing to speak up.
References
- DEA — Ketamine Drug Information — Federal scheduling, diversion risks, and regulatory requirements for ketamine
- Substance Abuse and Mental Health Services Administration (SAMHSA) — Prescription Drug Monitoring Programs — Overview of PDMP systems and their role in preventing controlled substance misuse
- Schak KM, et al. (2016). Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. American Journal of Psychiatry, 173(3), 215-218 — Clinical concerns about ketamine misuse in therapeutic contexts
- Liu Y, et al. (2016). Ketamine Abuse Potential and Use Disorder. Brain Research Bulletin, 126(Pt 1), 68-73 — Research on ketamine's misuse potential and risk factors
- Short B, et al. (2018). Side-Effects Associated with Ketamine Use in Depression: A Systematic Review. Lancet Psychiatry, 5(1), 65-78 — Systematic review including misuse-related adverse effects
- NIH National Institute on Drug Abuse — Ketamine DrugFacts — Federal resources on ketamine pharmacology and misuse potential
Share